Re-issued: MAY 2018

SEXUAL HEALTH – EHC FORM

(These details must be uploaded to PharmOutcomes within 24 hours of the consultation)

Name				Date of Bir	th	/ /		Age	
Postcode:			Fthnicity			Consultatio	on		
1 osteode.			Limiting			time			
ASSESSMENT OF F	RASER CO	MPETENCY (15 an	d under)						
Does the young person understand that the consultation is confidential:									es / No
Does the young person appear to understand the advice given including side effects and								Y	es / No
contraindications of treatment?									
Have you discussed	d with the	young person abo	ut informing he	r parents abo	out the trea	atment?		Y	es / No
Is the treatment in	the young	g person's best inte	erests?					Y	es / No
	_	n to the effect on t	he physical or n	nental health	of the you	ing person if	f advi	ce Y	es / No
			nd under)						
Is there any evidence of abuse or neglect?									es / No
•									es / No
Postcode: Ethnicity Consultation Ethnicity Consultation Ethnicity Consultation Ethnicity Consultation Ethnicity Consultation Ethnicity Et					es / No				
						Y	es / No		
								os / No	
, , , , , , , , , , , , , , , , , , , ,								es / No es / No	
•		mich lead you to b	e concerned ab	out the youn,	g person s	salety of we	enare	ii i	ES / NO
								V	es / No
								es / No	
								es / No	
iviisseu piii or other normonal contraceptive error							'	C3 / 140	
Vomited previous EHC							Y	es / No	
Reduced pill efficacy due to vomiting / diarrhoea							Y	es / No	
									es / No
Other – please spe	ecify	•							
Date of UPSI		Time of UPSI		Time since	0-24	25-48	49-	-72	>72
				UPSI	hours	hours	hou	urs l	hours
MENSTRUAL HISTO	ORY								
	Yes No	First day of LMP		•					
				cycle					
						unknown	type	0	
		his cycle where EH	C was NOT take	en					es / No
Was LMP abnormal?								es / No	
Previous use of EHC this cycle								es / No	
Medical history taken, discussing inclusion criteria for Levonorgestrel PGD? Completed						Y	es / No		
		NIC AND CALITION	•	Res	uit of preg	nancy test			
			15						TICK
			ulipristal acotot	at an altern	ativo provi	dor			TICK
			•		ative provi	uer			
•		· · · · · · · · · · · · · · · · · · ·	ion within the la	ast live days					
Unexplained or unusual vaginal bleeding									
•			tose intoleranc	e. the Lann la	ctase defi	ciency or glu	ICOSE-	_	
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption									

Re-issued: MAY 2018

Cont'd						
Patient is receiving concomitant medication or treatment which makes						
Levonorgestrel contraindicated						
None of the above						
Taking enzyme inducing medications?						
BMI over 26 or Weight > 70kg						
Medicine supplied?						
Product supplied Levonorgestrel 1.5mg tablets1						
Quantity (Quantity may be 2 if patient taking enzyme inducers or BMI over 26)						
Batch Number		Expiry Date				

ADVICE TO CLIENT LEVONORGESTREL - TICK TO INDICATE DISCUSSION

- The patient/carer should be given the following information verbally if appropriate and requested:
- Advice to client
- Effectiveness of method, dependent on length of time from UPSI/potential contraceptive failure to treatment
- Beneficial effects, side effects and risks should be discussed
- How to take the pill correctly, preferably as an immediate dose in the pharmacy.
- Breastfeeding mothers may be allowed to take away with them to allow them to feed their child before taking. This should only occur if it fits within the allowed time limits
- If vomiting occurs within two hours of taking, a repeat dose is required see 'Use outside the terms of the product licence' in PGD
- When to seek further medical advice e.g. INR check if on warfarin
- To refer to Sexual Health Clinic or GP if no/light period up to three weeks after treatment Discuss ongoing contraception including Quick Starting Contraception guidance recommending starting contraception immediately after oral emergency hormonal contraception with additional protection as appropriate for the method used
- Discuss long-acting reversible contraception and give written information that is in line with NICE guidance, CG30, October 2005
- Encourage use of condoms and reinforce the safer sex message

I agree that the above is a true record of my conversation/ consultation with the pharmacist and agree to this information being logged on PharmOutcomes system in order for the pharmacy to reclaim payment for service provided

- Recommend sexually transmitted infections screening Supply or recommend condoms as detailed in the service specification
- Use of the product outside the terms of its licence should be discussed with the patient, including the reasons why this may be necessary
- Advise where the patient will continue to use a hormonal method of contraception that they should use an additional contraceptive method for 7 days (2 days for progestogen-only pill 9 days for Qlaira)

CONDOM SUPPLY - APPEARS FOR UNDER 25S Quantity supplied Condoms offered? Yes / No REFERRAL INFORMATION Referral necessary? Yes / No Copper IUD fitting Yes / No More than 72 hours since UPSI - EHC not supplied Yes / No Unable to give consent - EHC not supplied Yes / No Falls into exclusion criteria in PGD - EHC not supplied Yes / No Suspected pregnancy - EHC not supplied Yes / No Other - *please specify* No referral needed Yes / No Other Notes Name of Pharmacist (PRINT) Signature: **Customer Signature:** Patient/customer Consent: This section must be signed